DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Junsik | ko |
dc.contributor.author | Kim, Jung Chul | ko |
dc.contributor.author | Lee, Miran | ko |
dc.contributor.author | Lee, Joohyang | ko |
dc.contributor.author | Kim, Yoo-Na | ko |
dc.contributor.author | Lee, Yong Jae | ko |
dc.contributor.author | Kim, Sunghoon | ko |
dc.contributor.author | Kim, Sang Wun | ko |
dc.contributor.author | Park, Su-Hyung | ko |
dc.contributor.author | Lee, Jung-Yun | ko |
dc.date.accessioned | 2023-12-06T05:00:55Z | - |
dc.date.available | 2023-12-06T05:00:55Z | - |
dc.date.created | 2023-10-30 | - |
dc.date.created | 2023-10-30 | - |
dc.date.issued | 2023-11 | - |
dc.identifier.citation | BRITISH JOURNAL OF CANCER, v.129, no.11, pp.1841 - 1851 | - |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.uri | http://hdl.handle.net/10203/315817 | - |
dc.description.abstract | Background :Poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPis) are becoming the standard of care for epithelial ovarian cancer (EOC). Recently, clinical trials of triple maintenance therapy (PARPi+anti-angiogenic agent+anti-PD-1/L1) are actively ongoing. Here, we investigated the immunological effects of PARPi or triple maintenance therapy on T cells and their impact on clinical responses.Methods :We collected serial blood from EOC patients receiving PARPi therapy (cohort 1: PARPi, n = 49; cohort 2: olaparib+ bevacizumab+ pembrolizumab, n = 31). Peripheral T cells were analyzed using flow cytometry and compared according to the PARPi response. Progression-free survival (PFS) was assessed according to prognostic biomarkers identified in a comparative analysis.Results :Regulatory T cells (Tregs) were suppressed by PARPi therapy, whereas PD-1 was not significantly changed. Short PFS group exhibited a higher percentage of baseline PD-1(+)Tregs than long PFS group, and the patients with high percentage of PD-1(+)Tregs before treatment showed poor PFS in cohort 1. However, the expression of PD-1 on Tregs significantly decreased after receiving triple maintenance therapy, and the reduction in PD-1+Tregs was associated with superior PFS in cohort 2 (P = 0.0078).ConclusionPARPi suppresses Tregs, but does not affect PD-1 expression. Adding anti-PD-1 to PARPi decreases PD-1(+)Tregs, which have negative prognostic value for PARPi monotherapy. | - |
dc.language | English | - |
dc.publisher | SPRINGERNATURE | - |
dc.title | Frequency of peripheral PD-1+regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer | - |
dc.type | Article | - |
dc.identifier.wosid | 001084002000001 | - |
dc.identifier.scopusid | 2-s2.0-85173854536 | - |
dc.type.rims | ART | - |
dc.citation.volume | 129 | - |
dc.citation.issue | 11 | - |
dc.citation.beginningpage | 1841 | - |
dc.citation.endingpage | 1851 | - |
dc.citation.publicationname | BRITISH JOURNAL OF CANCER | - |
dc.identifier.doi | 10.1038/s41416-023-02455-z | - |
dc.contributor.localauthor | Park, Su-Hyung | - |
dc.contributor.nonIdAuthor | Park, Junsik | - |
dc.contributor.nonIdAuthor | Kim, Jung Chul | - |
dc.contributor.nonIdAuthor | Lee, Miran | - |
dc.contributor.nonIdAuthor | Lee, Joohyang | - |
dc.contributor.nonIdAuthor | Kim, Yoo-Na | - |
dc.contributor.nonIdAuthor | Lee, Yong Jae | - |
dc.contributor.nonIdAuthor | Kim, Sunghoon | - |
dc.contributor.nonIdAuthor | Kim, Sang Wun | - |
dc.contributor.nonIdAuthor | Lee, Jung-Yun | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | PD-1 | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | ANTITUMOR | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.